Active substance
Results for the substance sacituzumab govitecan
1 result
About this active substance
Sacituzumab govitecan is an antibody-drug conjugate used in the treatment of metastatic triple-negative breast cancer (TNBC) and other advanced cancers. It consists of a monoclonal antibody targeting the Trop-2 protein, which is frequently expressed on the surface of tumor cells, and a chemotherapeutic agent (SN-38) that is directly delivered into cancer cells.
Sacituzumab govitecan is administered intravenously, usually once weekly, and is indicated for patients with TNBC who have previously received at least two lines of systemic therapy. It is used to reduce tumor size, slow disease progression, and improve overall survival.
Common side effects include nausea, diarrhea, fatigue, alopecia, and neutropenia. In rare cases, severe adverse reactions such as hypersensitivity reactions or hematologic toxicity may occur. Regular monitoring of hematologic parameters and liver function is essential.
Sacituzumab govitecan represents an innovative therapeutic option for patients with advanced cancer, offering a targeted and effective approach to treating aggressive tumors.
Sacituzumab govitecan is administered intravenously, usually once weekly, and is indicated for patients with TNBC who have previously received at least two lines of systemic therapy. It is used to reduce tumor size, slow disease progression, and improve overall survival.
Common side effects include nausea, diarrhea, fatigue, alopecia, and neutropenia. In rare cases, severe adverse reactions such as hypersensitivity reactions or hematologic toxicity may occur. Regular monitoring of hematologic parameters and liver function is essential.
Sacituzumab govitecan represents an innovative therapeutic option for patients with advanced cancer, offering a targeted and effective approach to treating aggressive tumors.